Cargando…

Screening and validation of novel serum panel of microRNA in stratification of prostate cancer

BACKGROUND: Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Manoj, Anveshika, Ahmad, Mohammad K., Prasad, Gautam, Kumar, Durgesh, Mahdi, Abbas A., Kumar, Manoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513910/
https://www.ncbi.nlm.nih.gov/pubmed/37745909
http://dx.doi.org/10.1016/j.prnil.2023.06.002
_version_ 1785108618036641792
author Manoj, Anveshika
Ahmad, Mohammad K.
Prasad, Gautam
Kumar, Durgesh
Mahdi, Abbas A.
Kumar, Manoj
author_facet Manoj, Anveshika
Ahmad, Mohammad K.
Prasad, Gautam
Kumar, Durgesh
Mahdi, Abbas A.
Kumar, Manoj
author_sort Manoj, Anveshika
collection PubMed
description BACKGROUND: Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification. MATERIALS AND METHODS: The present study demonstrates the comparative expression profiles of miRNA-141,-1290,-100, and -335 in both tissue and serum, including Benign Prostate Hyperplasia (BPH) and PCa, with healthy volunteers. Firstly, we demonstrate the expression of all miRNAs in the discovery cohort, including metastasis and benign tissue, and later validate their non-invasive diagnostic potential in BPH and PCa with healthy volunteers. MiRNA was isolated from tissue and serum to be quantified by RT-PCR and analyzed for biomarker potential by receiver operating characteristic (ROC) curve analysis, followed by targetome analysis of each miRNA. RESULTS: Among the non-invasive miRNA assessed, it was seen that miRNA 141 (P = 0.0003) and miRNA 1290 (P < 0.0001) are oncogenic with significantly higher expression, while miRNA 100 (P = 0.0002) and miRNA 335 are tumor suppressor, in PCa as compared to controls. While for BPH, miRNA 141 (P = 0.003) and miRNA 335 (P = 0.0002) were found to be significantly oncogenic and tumor suppressors, respectively. The analysis of the ROC curve of panel miRNAs (miRNA-141,-1290, and -100) portrayed a significant area under the curve with greater sensitivity and specificity. Moreover, in-silico prediction of their respective targetomes represents their extensive involvement in PCa progression and various other cascades that aid in PCa networks. CONCLUSIONS: To the best of our knowledge, we are going to report for the first time this panel of miRNA that can be used to accurately and efficiently diagnose BPH and PCa patients from healthy males.
format Online
Article
Text
id pubmed-10513910
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Asian Pacific Prostate Society
record_format MEDLINE/PubMed
spelling pubmed-105139102023-09-23 Screening and validation of novel serum panel of microRNA in stratification of prostate cancer Manoj, Anveshika Ahmad, Mohammad K. Prasad, Gautam Kumar, Durgesh Mahdi, Abbas A. Kumar, Manoj Prostate Int Research Article BACKGROUND: Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification. MATERIALS AND METHODS: The present study demonstrates the comparative expression profiles of miRNA-141,-1290,-100, and -335 in both tissue and serum, including Benign Prostate Hyperplasia (BPH) and PCa, with healthy volunteers. Firstly, we demonstrate the expression of all miRNAs in the discovery cohort, including metastasis and benign tissue, and later validate their non-invasive diagnostic potential in BPH and PCa with healthy volunteers. MiRNA was isolated from tissue and serum to be quantified by RT-PCR and analyzed for biomarker potential by receiver operating characteristic (ROC) curve analysis, followed by targetome analysis of each miRNA. RESULTS: Among the non-invasive miRNA assessed, it was seen that miRNA 141 (P = 0.0003) and miRNA 1290 (P < 0.0001) are oncogenic with significantly higher expression, while miRNA 100 (P = 0.0002) and miRNA 335 are tumor suppressor, in PCa as compared to controls. While for BPH, miRNA 141 (P = 0.003) and miRNA 335 (P = 0.0002) were found to be significantly oncogenic and tumor suppressors, respectively. The analysis of the ROC curve of panel miRNAs (miRNA-141,-1290, and -100) portrayed a significant area under the curve with greater sensitivity and specificity. Moreover, in-silico prediction of their respective targetomes represents their extensive involvement in PCa progression and various other cascades that aid in PCa networks. CONCLUSIONS: To the best of our knowledge, we are going to report for the first time this panel of miRNA that can be used to accurately and efficiently diagnose BPH and PCa patients from healthy males. Asian Pacific Prostate Society 2023-09 2023-06-21 /pmc/articles/PMC10513910/ /pubmed/37745909 http://dx.doi.org/10.1016/j.prnil.2023.06.002 Text en © 2023 The Asian Pacific Prostate Society. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Manoj, Anveshika
Ahmad, Mohammad K.
Prasad, Gautam
Kumar, Durgesh
Mahdi, Abbas A.
Kumar, Manoj
Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title_full Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title_fullStr Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title_full_unstemmed Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title_short Screening and validation of novel serum panel of microRNA in stratification of prostate cancer
title_sort screening and validation of novel serum panel of microrna in stratification of prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513910/
https://www.ncbi.nlm.nih.gov/pubmed/37745909
http://dx.doi.org/10.1016/j.prnil.2023.06.002
work_keys_str_mv AT manojanveshika screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer
AT ahmadmohammadk screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer
AT prasadgautam screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer
AT kumardurgesh screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer
AT mahdiabbasa screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer
AT kumarmanoj screeningandvalidationofnovelserumpanelofmicrornainstratificationofprostatecancer